Clinical Trials
60 trialsBrodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
National Institutes of Health Clinical Center (CC)
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
iCaRe2
University of Nebraska
DP-04
AstraZeneca
ELEPHAS-02
Elephas
CER
Cancer Support Community, Research and Training Institute, Philadelphia
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
Istituto Oncologico Veneto IRCCS
SELECT-CAR-NK
Essen Biotech
EBNK-ST-001
Essen Biotech
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
SCORE
Natera, Inc.
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
ELEPHAS-05
Elephas
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
AYAConnect
UNC Lineberger Comprehensive Cancer Center
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
EARN
Washington University School of Medicine
DELFI-L101
Delfi Diagnostics Inc.
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Milton S. Hershey Medical Center
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Tvardi Therapeutics, Incorporated
ROOT
Taproot Health
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DUET-3
Xencor, Inc.
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
UPLIFT
Massachusetts General Hospital
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Collecting Solid Tumor Tissue to Identify New Treatments
National Institutes of Health Clinical Center (CC)
DUET-4
Xencor, Inc.
CheckMate 76U
Bristol-Myers Squibb
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
DUET-2
Xencor, Inc.
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
ONCOPRO
Hospices Civils de Lyon
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
PIONEER
SpeciCare
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
National Institutes of Health Clinical Center (CC)
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
National Institutes of Health Clinical Center (CC)
N1
CureOne
EPAC
Stanford University
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
OrienGene Biotechnology Ltd.
Safety Study of Modified Vaccinia Virus to Cancer
University of Pittsburgh